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Trichomonas vaginalis is a prevalent sexually transmitted infection (STI).
Diagnosis has historically relied on either microscopic analysis or culture, the latter being
the previous gold standard. However, these tests are not readily available for male diagnosis, generally only perform well for symptomatic women, and are not as sensitive as
nucleic acid ampliﬁcation tests (NAATs). Men are largely asymptomatic but carry the organism and transmit to their sexual partners. This multicenter, prospective study evaluated the performance of the cobas T. vaginalis/Mycoplasma genitalium (TV/MG) assay
for detection of T. vaginalis DNA compared with patient infection status (PIS) deﬁned by
a combination of commercially available NAATs and culture using urogenital specimens.
A total of 2,064 subjects (984 men and 1,080 women, 940 [45.5%] symptomatic, 1,124
[54.5%] asymptomatic) were evaluable. In women, sensitivity ranged from 99.4% (95%
conﬁdence interval [CI] 96.8 to 99.9%) using vaginal samples to 94.7% (95% CI 90.2 to
97.2%) in PreservCyt samples. Speciﬁcity ranged from 98.9 to 96.8% (95% CI 95.4 to
97.8%). In men, the cobas TV/MG assay was 100% sensitive for the detection of T. vaginalis in both male urine samples and meatal swabs, with speciﬁcity of 98.4% in urine
samples and 92.5% in meatal swabs. The cobas TV/MG is a suitable diagnostic test for
the detection of T. vaginalis, which could support public health efforts toward infection
control and complement existing STI programs.

Citation Van Der Pol B, Rao A, Nye MB,
Chavoustie S, Ermel A, Kaplan C, Eisenberg D,
Chan PA, Mena L, Pacheco S, Waites KB, Xiao L,
Krishnamurthy S, Mohan R, Bertuzis R,
McGowin CL, Arcenas R, Marlowe EM, Taylor
SN. 2021. Trichomonas vaginalis detection in
urogenital specimens from symptomatic and
asymptomatic men and women by use of the
cobas TV/MG test. J Clin Microbiol 59:e0026421. https://doi.org/10.1128/JCM.00264-21.
Editor Bobbi S. Pritt, Mayo Clinic
Copyright © 2021 Van Der Pol et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.

KEYWORDS NAAT, Trichomonas vaginalis, molecular methods, urogenital

Address correspondence to Barbara Van Der
Pol, bvanderp@uab.edu.

T

Received 5 February 2021
Returned for modiﬁcation 11 April 2021
Accepted 6 July 2021

richomonas vaginalis is considered one of the most common curable sexually
transmitted infections (STIs) (1, 2), with the World Health Organization (WHO) estimating 156 million cases in 2016, a higher prevalence than Chlamydia trachomatis,
Neisseria gonorrhoeae, or syphilis (3). T. vaginalis is currently not a reportable disease
and the true estimation of disease prevalence is not currently known. Some of the
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factors contributing to this are a lack of routine testing and nonspeciﬁc symptomatology, and infected men being predominantly asymptomatic (4, 5).
A large proportion of T. vaginalis infections are asymptomatic; however, symptoms
can include urethral discharge, primarily in males, and abnormal vaginal discharge,
dysuria, itching, irritation, and abdominal pain in females (1). The consequences of
untreated T. vaginalis infection may include pelvic inﬂammatory disease (PID) and
adverse outcomes of pregnancy (6). T. vaginalis infection has also been shown to
increase the risk of HIV by 50% via several mechanisms, including damage to the vaginal epithelial membrane by the protozoa (6).
The Centers for Disease Control and Prevention (CDC) recommends that women
presenting with symptoms are tested for T. vaginalis, but do not recommend generalized screening of asymptomatic women (7). However, screening is recommended for
women living in areas with higher than average prevalence or those who report behaviors
that may have resulted in exposure to STIs, or who are HIV positive (8). Coinfection of T.
vaginalis with C. trachomatis and/or N. gonorrhoeae in women has been previously
reported (9) and symptoms can overlap between infections. Therefore, T. vaginalis infections may be missed and left untreated if C. trachomatis and/or N. gonorrhoeae positivity is
presumed to be the cause. In populations with high levels of STI exposure, the inclusion of
T. vaginalis testing alongside C. trachomatis/N. gonorrhoeae testing is likely to dramatically
increase case ﬁnding (10). A study by Sena et al. looked at the prevalence of T. vaginalis
infections in the male partners of women with trichomoniasis and observed that 71.7% of
the men were also infected, of which 77.3% were asymptomatic (11). Men are seldom
tested for T. vaginalis at the time of testing for C. trachomatis/N. gonorrhoeae due to a lack
of recommendations and testing methodologies, which is further complicated by the
largely asymptomatic nature of T. vaginalis infections. Reliable testing platforms and more
data are needed to understand the true prevalence of symptomatic and asymptomatic
infections, particularly in male populations.
Laboratory diagnosis of T. vaginalis previously relied on either microscopic analysis of a saline wet mount prepared from the female patient’s discharge, examination of spun sediment in male urine (rarely available in outpatient settings), or culture, the latter formerly being the gold standard (7, 12). These tests are highly
speciﬁc, although they generally only perform well for symptomatic women and,
even then, they are not as sensitive as nucleic acid ampliﬁcation tests (NAATs) (7,
12). NAATs for T. vaginalis are available, such as the Aptima CV/TV assay (Hologic,
San Diego, USA), the cobas TV/MG assay (Roche Diagnostics, Pleasanton, USA),
Xpert TV (Cepheid, Sunnydale, USA), and Amplivue Trichomonas Assay (Quidel
Corporation, Athens, USA). There are limited studies available on the performance
of these assays; however, they generally demonstrate more than 96% sensitivity for
the detection of T. vaginalis (13–15).
The objective of this study was to evaluate the performance of a new NAAT, the
cobas TV/MG assay performed on the cobas 6800/8800 systems, for the detection of T.
vaginalis in symptomatic and asymptomatic male and female urogenital samples, compared to a prespeciﬁed patient infection status (PIS). The PIS was deﬁned using a combination of a Food and Drug Administration (FDA)-cleared NAAT and T. vaginalis
culture.
MATERIALS AND METHODS
Patient population and ethics. This multicenter, prospective clinical study recruited participants at
nine sites in the USA: Birmingham, AL; Indianapolis, IN; Jackson, MS; Miami, FL; New Haven, CT; New
Orleans, LA; Oakland, CA; Providence, RI; and St. Louis, MO. Male and female patients, whether symptomatic or asymptomatic, were eligible if they were (i) aged $14 years, (ii) reported sexual activity within
the past 6 months, and (iii) were attending family planning, obstetrics and gynecology, or STI clinics.
Patients were ineligible if they had (i) previously enrolled in the study; (ii) used antimicrobial
agents active against T. vaginalis (metronidazole or tinidazole) within the 21 days prior to sample
collection; (iii) used Replens (Church & Dwight, Co., Inc., Princeton, NJ), RepHresh Odor Eliminating
Vaginal Gel (Church & Dwight, Co., Inc., Princeton, NJ), RepHresh Clean and Balance (Church &
Dwight, Co., Inc., Princeton, NJ) or products containing metronidazole within 21 days prior to
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specimen collection; (iv) had undergone a total hysterectomy; or (v) had a contraindication to the
Papanicolaou test or cervical sampling.
Participants were classiﬁed as symptomatic for T. vaginalis infection if they reported any of the following: dysuria; coital issues (pain, difﬁculty, or bleeding); pelvic pain; abnormal vaginal discharge; unusual vaginal odor; pelvic, uterine or ovarian pain; penile discharge; testicular pain; scrotal pain; or swelling, itching, burning, redness, or soreness of the genitals. This study was conducted in compliance with
the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines and the US
FDA regulations. The study protocol was submitted to an Institutional Review Board (IRB) to ensure the
local and FDA requirements were met prior to the start of the study. All participants were required to
provide informed signed consent. This manuscript was prepared in accordance with the STARD guidelines for reporting of clinical studies (16).
Specimen collection. Women provided specimens in the following order: a ﬁrst catch urine (FCU);
vaginal swabs; an endocervical swab in cobas PCR medium; and a cervical specimen in PreservCyt solution obtained with a spatula, cytobrush, or broom. Participants were randomized to either the selfobtained or the clinician-obtained arm for collection of vaginal swabs used in the cobas assay.
Participants within the self-collected arm obtained their self-collected vaginal swab ﬁrst, and the remaining swabs were clinician-collected. In the clinician-collected arm, all vaginal swabs were clinician collected. The T. vaginalis swabs were collected as follows; Hologic APTIMA TV assay, the cobas TV assay,
and ﬁnally the InPouch TV assay (Biomed Diagnostics, White City, OR) specimen, which was collected
last in the series due to the use of a speculum. Following collection, the clinician transferred the swabs to
the relevant transport medium, as per the respective comparator test’s standard procedure. Participants
randomized to the clinician-collected arm had their vaginal swab specimen for cobas testing collected by
the clinician. Both the endocervical swab and the liquid-based cytology (LBC) sample were collected for
assessment with the cobas assay only.
Men ﬁrst provided self- or clinician-collected meatal swabs (collected in randomized order) for use
with the cobas test, followed by an FCU sample. The FCU sample was aliquoted into the manufacturer’s
collection device for the test assays as per the instructions for use (the penile meatal swab is not an
FDA-cleared sample type for the detection of TV in the cobas TV/MG assay for use on the cobas 6800/
8800 systems).
Sample testing. Testing with the cobas TV/MG was performed at three sites using at least three lots
of investigational reagents. All cobas specimens from a single subject were tested at one individual test
site. Specimens from runs with control/operator failures were retested if sufﬁcient sample remained, and
individual invalid results were also repeated if sample volume allowed. If invalid results remained invalid
upon retesting and there was insufﬁcient volume for further testing, the result remained invalid.
Female and male urogenital specimens were assessed by NAAT using the APTIMA TV assay and the
Cepheid Xpert TV assay (Cepheid, Sunnyvale, CA, USA), respectively, and the InPouch TV Culture System.
For female samples, the PIS was deemed positive if their vaginal samples tested positive by either the
APTIMA TV assay or the InPouch TV Culture System tests, in accordance with FDA guidelines (17) at the
time of the study inception. A negative culture result, plus an invalid NAAT result, was deemed as indeterminate. For male samples, the PIS was deemed positive if male urine samples tested positive via either the Cepheid Xpert TV assay or the InPouch TV Culture System. Again, where there was a negative
result and an invalid result, the PIS was deemed indeterminate.
Data analysis. Test results for each assay were interpreted according to the instructions for use. All
data analyses were performed using SAS/STAT software (version 9.4) (SAS Institute Inc., Cary, NC, USA)
and in accordance with FDA guidance (18). The clinical performance of the cobas test for the detection
of T. vaginalis was evaluated by comparing test results for each sample type to the PIS. The sensitivity,
speciﬁcity, positive predictive value (PPV), and negative predictive value (NPV) were calculated by sex,
specimen type, and symptom status and compared to an infected status algorithm for each sex. In the
algorithm, the designation of a subject as infected or noninfected was based on the combination of
results obtained from comparator assays. Additionally, results were analyzed separately for self-collected
and clinician-collected vaginal and penile meatal swab specimens and by testing sites. The two-sided
95% conﬁdence intervals (CIs) for the estimates of sensitivity, speciﬁcity, PPV, and NPV were estimated
using the Score method (19).

RESULTS
Patient characteristics. A total of 2,064 subjects were evaluable for T. vaginalis,
including 984 men and 1,080 women (Table 1). Twenty-six samples were excluded
from T. vaginalis analyses for invalid results, protocol deviation, or insufﬁcient sample
volume: 3 female urine, 1 clinician-collected vaginal swab sample, 1 self-collected vaginal swab sample, 6 PreservCyt samples, 6 endocervical swab samples, 1 male urine
sample, 2 male clinician-collected samples, 2 male self-collected samples, 1 vaginal
swab without collection method information (self or clinician) and 3 meatal swabs
without collection method information (self or clinician). Of the women in the ﬁnal
analysis, 542 were included in the clinician-collected and 535 were included in the selfcollected arm of the study, with 1,074 women providing valid samples for PreservCyt
and endocervical swab analysis and 1,077 women providing valid urine samples. Of
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TABLE 1 Baseline demographics and characteristics
Characteristica
Total (n)

Value(s)
2,064

Age, yrs (mean 6 SD)
Male (n [%])
Female (n [%])

35.5 6 12.5
984 (47.7)
1,080 (52.3)

American Indian/Alaskan Native (n [%])
Asian (n [%])
Black/African American (n [%])
Native Hawaiian/Paciﬁc Islander (n [%])
White (n [%])
Multiple/other (n [%])
Not reported (n [%])

3 (0.1)
13 (0.6)
1,433 (69.4)
5 (0.2)
536 (26.0)
54 (2.6)
20 (1.0)

Symptomatic (n [%])
Asymptomatic (n [%])

940 (45.5)
1,124 (54.5)

Pregnant (female only (n [%]))

3 (0.3)

Family planning clinic (n [%])
Obstetrics/gynecology clinic (n [%])
STI clinic (n [%])
Family planning/STI clinic (n [%])

521 (25.2)
260 (12.6)
741 (35.9)
542 (26.3)

number of samples; SD, standard deviation; STI, sexually transmitted infection.

the men, 488 were included in the clinician-collected meatal arm and 489 were included
in the self-collected meatal arm of the study. A total of 983 men provided valid urine samples for analysis. Positivity for T. vaginalis in this study, based on the PIS, was 15.8% (171/
1,080) among all women, and 2.3% (23/983) among all men evaluated (Table 2). The prevalence of T. vaginalis in asymptomatic and symptomatic women was 12.1% (55/455) and
18.6% (11/625), respectively. The prevalence of T. vaginalis in asymptomatic and symptomatic men was 1.5% (10/668) and 4.1% (13/315), respectively. Additional information
regarding male and female T. vaginalis positivity by state location can be found in Table
S1 in the supplemental information.
Assay performance for the detection of T. vaginalis. For female specimens (asymptomatic and symptomatic) the sensitivity ranged from 99.4% (95% CI 96.8 to 99.9%) for
vaginal samples to 94.7% (95% CI 94.1 to 99.1%) for LBC samples in PreservCyt
(Table 2). Speciﬁcity across the female specimen types was .96.8%. The cobas TV/MG
assay was 100% sensitive for the detection of T. vaginalis in both male urine samples
and meatal swabs. Speciﬁcity of the cobas assay was higher in male urine samples
(98.4%) compared with meatal swabs (92.5%).
Compared with patient infection status (PIS), both clinician-collected and self-collected male and female samples had similar performance with the cobas TV assay
(Table 3). Self-collected vaginal swab samples had slightly higher sensitivity and speciﬁcity versus clinician-collected samples; however, the differences were not signiﬁcant
(P = 1.00 and P = 0.21 for sensitivity and speciﬁcity, respectively). Self-collected meatal
swab samples showed similar sensitivity (both 100%) and speciﬁcity (92.5% versus
92.6%) performance to clinician-collected samples (P = 1.00 for both sensitivity and
speciﬁcity, respectively). In female samples, the PPV of the cobas assay for T. vaginalis
across different clinics and sample types was 50.0 to 100% and the NPV was 97.3 to
100% (Table S2). In male samples, the PPV of the cobas assay for T. vaginalis was 13.3
to 100% and the NPV was 100% (Table S2).
Figure 1 illustrates cobas T. vaginalis positivity across all samples, regardless of
infection status. For female samples, most positive samples were positive across all
sample types (Fig. 1A). In Fig. 1B, the data show 71/104 meatal swab-only positives. For
male urine, only 23/41 positives were conﬁrmed by PIS. However, the cobas meatal
swab and urine results were both positive for 10 patients not identiﬁed as such by the
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Sample type
Female participants
Urine
Symptomatic
Asymptomatic
Overall
Vaginal swab (both clinicianand self-collected)
Symptomatic
Asymptomatic
Overall
PreservCyt samples
Symptomatic
Asymptomatic
Overall
Endocervical swab
Symptomatic
Asymptomatic
Overall
All female subjectsb
Symptomatic
Asymptomatic
Overall
Male participants
Urine
Symptomatic
Asymptomatic
Overall
Meatal swab (both clinicianand self-collected)
Symptomatic
Asymptomatic
Overall
All male subjectsb
Symptomatic
Asymptomatic
Overall

Total (N)

% Prevalence (n/N)

% Sensitivity (n/N)

95% CI

% Speciﬁcity (n/N)

95% CI

622
455
1,077

18.6 (116/622)
12.1 (55/455)
15.9 (171/1077)

97.4 (113/116)
98.2 (54/55)
97.7 (167/171)

92.7–99.1
90.4–99.7
94.1–99.1

98.8 (500/506)
98.5 (394/400)
98.7 (894/906)

97.4–99.5
96.8–99.3
97.7–99.2

623
454
1,077

18.6 (116/623)
12.1 (55/454)
15.9 (171/1077)

100 (116/116)
98.2 (54/55)
99.4 (170/171)

96.8–100
90.4–99.7
96.8–99.9

97.0 (492/507)
96.5 (385/399)
96.8 (877/906)

95.2–98.2
94.2–97.9
95.4–97.8

622
452
1,074

18.5 (115/622)
12.2 (55/452)
15.8 (170/1074)

93.9 (108/115)
96.4 (53/55)
94.7 (161/170)

88.0–97.0
87.7–99.0
90.2–97.2

99.2 (503/507)
98.5 (391/397)
98.9 (894/904)

98.0–99.7
96.7–99.3
98.0–99.4

620
454
1,074

18.5 (115/620)
12.1 (55/454)
15.8 (170/1074)

97.4 (112/115)
98.2 (54/55)
97.6 (116/170)

92.6–99.1
90.4–99.7
94.1–99.1

98.8 (499/505)
97.2 (388/399)
98.1 (887/904)

97.4–99.5
95.1–98.5
97.0–98.8

625
455
1,080

18.6 (116/625)
12.1 (55/455)
15.8 (171/1080)

315
668
983

4.1 (13/315)
1.5 (10/668)
2.3 (23/983)

100 (13/13)
100 (10/10)
100 (23/23)

77.2–100
72.2–100
85.7–100

98.3 (297/302)
98.5 (648/658)
98.4 (945/960)

96.2–99.3
97.2–99.2
97.4–99.1

315
662
977

4.1 (13/315)
1.7 (11/662)
2.5 (24/977)

100 (13/13)
100 (11/11)
100 (24/24)

77.2–100
74.1–100
86.2–100

91.1 (275/302)
93.2 (607/651)
92.5 (882/953)

87.3–93.8
91.0–94.9
90.7–94.1

315
668
983

4.1 (13/315)
1.5 (10/668)
2.3 (23/983)

aCI,

conﬁdence interval; N, total number of samples; n, number of T. vaginalis-positive samples (for prevalence), number of positive samples with accurate result (for
sensitivity), or number of negative samples with accurate result (for speciﬁcity); PIS, patient infected status.
bThese numbers represent the overall prevalence of TV infection in male and female subjects.

PIS. On average, both male urine and meatal swab samples that were positive by
cobas and negative by PIS had higher cycle threshold (CT) values compared with
those samples positive by both cobas and PIS (Fig. 2). The CT values for male urine
and meatal swab samples that were positive by the cobas assay can be found in
Table S3.
DISCUSSION
In this study, the cobas assay was highly sensitive and speciﬁc for the detection
of T. vaginalis in both male and female urogenital samples, with sensitivities greater
than or similar to those seen with other NAATs for T. vaginalis (7, 9, 12, 20, 21). The
sensitivity and speciﬁcity of cobas, when compared to the PIS, showed that male
urine samples and female vaginal swab samples are preferred for detection of T.
vaginalis infection. It is interesting to observe that regardless of the PIS, cobas TVpositive results for men show a higher detection rate in penile meatal swabs (104)
versus urine (41), and only 33 men had T. vaginalis detected in both their urine and
meatal swab samples (Fig. 1B). A previous study observed that among the paired
specimens of meatal swabs and urine, T. vaginalis was detected in a higher percentage of meatal swabs compared with urine samples (80.4% versus 39.3%) (22).
Similar to our clinical trial study, Dize et al. collected the meatal swabs prior to the
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TABLE 3 Clinical performance of self-collected versus clinician collected vaginal/meatal swab samplesc
Sample type
Female vaginal swab samplesa
Clinician-collected
Symptomatic
Asymptomatic
Overall
Self-collected
Symptomatic
Asymptomatic
Overall
Male meatal swab samplesb
Clinician-collected
Symptomatic
Asymptomatic
Overall
Self-collected
Symptomatic
Asymptomatic
Overall

Total (N)

% Sensitivity (n/N)

95% CI

% Speciﬁcity (n/N)

95% CI

335
207
542

100 (71/71)
96.4 (27/28)
99.0 (98/99)

94.9–100
82.3–99.4
94.5–99.8

96.6 (255/264)
95.0 (170/179)
95.9 (425/443)

93.6–98.2
90.7–97.3
93.7–97.4

288
247
535

100 (45/45)
100 (27/27)
100 (72/72)

92.1–100
87.5–100
94.9–100

97.5 (237/243)
97.7 (215/220)
97.6 (452/463)

94.7–98.9
94.8–99.0
95.8–98.7

169
319
488

100 (7/7)
100 (7/7)
100 (14/14)

64.6–100
64.6–100
78.5–100

91.4 (148/162)
93.3 (291/312)
92.6 (439/474)

86.0–94.8
89.9–95.6
89.9–94.6

146
343
489

100 (6/6)
100 (4/4)
100 (10/10)

61.0–100
51.0–100
72.2–100

90.7 (127/140)
93.2 (316/339)
92.5 (443/479)

84.8–94.5
90.0–95.4
89.8–94.5

difference in sensitivity (95% CI) and speciﬁcity (95% CI) for clinician-collected versus self-collected vaginal swabs was 21.0 (23.0, 1.0), P = 1.00; and 21.7% (24.0%,
0.6%), P = 0.21, respectively.
bOverall difference in sensitivity (95% CI) and speciﬁcity (95% CI) for clinician-collected versus self-collected meatal swabs was 0% (223.2%, 30.9%), P = 1.00; and 0.1%
(23.2%, 3.5%), P = 1.00, respectively.
cCI, conﬁdence interval; N, total number of samples; n, number of positive samples with accurate result (for sensitivity) or number of negative samples with accurate result
(for speciﬁcity).

collection of urine (22). Another study also observed a higher detection rate among
the paired collections of meatal swabs (8.0%) versus urine (1.7%) (23). It is important to note that in this particular study, Chernesky et al. randomized the sequence
of collection between these two specimens (23) and therefore this mitigates the
concern that the meatal swab collected the majority of T. vaginalis if it was collected prior to the urine collection. This would suggest that the higher detection
rates in meatal swabs may be inherently due to the parasite’s pathophysiology; T.
vaginalis might adhere to the urethra and be less likely to detach in urine versus
other samples (24). The higher CT values for male samples positive by cobas and
negative by PIS compared with the lower CT values for samples positive by both
cobas and PIS may also indicate the increased sensitivity of cobas for detecting
samples with lower parasite load compared with the previous methods used to
deﬁne PIS (Fig. 2). Ultimately, the clinical signiﬁcance of meatal swabs as a viable alternative sample type compared to urine remains to be determined.
Although there are no ofﬁcial guidelines or recommendations for T. vaginalis
testing in men, if testing becomes readily available then those guidelines may
change, and male partners of females diagnosed with T. vaginalis infection can be
offered testing with urine or urethral swabs to conﬁrm diagnosis prior to treatment
(25). The clinical signiﬁcance and utility of the penile meatal swab is currently
unknown, although this sample has been shown to have potential utility in a number of studies for the detection of T. vaginalis and other STI pathogens (C. trachomatis, N. gonorrhea, and M. genitalium) (22, 23, 26). The collection process for penile
meatal swabs may also be more comfortable for patients compared with urethral
swab collection.
The high performance of the vaginal swab samples collected in cobas PCR medium
indicate that this sampling method is the optimal specimen type for use with the
cobas CT/NG assay, which should facilitate ease of testing during a patient clinic visit
(27). Only one sample tested positive with the APTIMA TV alone, in an asymptomatic
female patient, who would have been deﬁned by PIS as infected.
As noted, both the clinician-collected and self-collected male meatal and female
vaginal swab samples were highly sensitive and speciﬁc. This is very important, as selftesting can increase the likelihood that patients will access testing and, in light of the
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current COVID-19 pandemic and rising incidence of STIs, it may be increasingly important in enabling patients to access medical care and diagnosis (28).
The prevalence of T. vaginalis in this study, at 15.8% in female subjects and 2.3% in
male subjects, was higher than some previous estimates of T. vaginalis prevalence, particularly in asymptomatic female subjects, which was 12.1% in this study (7, 9, 12). The
prevalence of T. vaginalis in male subjects was low, as was expected based on data in
the literature (7, 12, 26), and may have been underestimated due to the collection of
meatal swabs prior to urine specimens which were used to deﬁne infection status. If
one assumes that those meatal swabs that gave positive results when the cobas urine
result was also positive, but where PIS was negative, were in fact true positives, then
positivity would have been 4.2% (41/983). Furthermore, if the 71 meatal samples that
were not conﬁrmed with other urine tests were compared head to head with meatal
samples using a comparator NAAT (which is a study limitation due to the lack of
another FDA-cleared NAAT for the detection of T. vaginalis in men) the positivity would
be estimated to be 11.5% (113/983).
In conclusion, the high performance of the cobas TV/MG assay for use on the cobas
6800/8800 systems, in both clinician- and self-collected urogenital samples from symptomatic and asymptomatic men and women, means the cobas assay can reliably
detect the presence and absence of T. vaginalis in urogenital samples and is a suitable clinical test for the diagnosis of T. vaginalis. The cobas 6800/8800 offers an optimal systems approach for use alongside other commercially available STI tests. The
October 2021 Volume 59 Issue 10 e00264-21

jcm.asm.org 7

Downloaded from https://journals.asm.org/journal/jcm on 25 February 2022 by 75.132.44.168.

FIG 1 Venn diagrams comparing the cobas T. vaginalis positives in female urogenital samples (A) and
male urogenital samples (B).

Van Der Pol et al.

Journal of Clinical Microbiology

FIG 2 Distribution of CT values from T. vaginalis positive results with the cobas TV/MG assay in evaluable
males. The diamonds represent the mean values and the lines inside the boxes represent the median
values. The error bars represent standard deviation, with the circles representing individual samples
outside of the error bars. CT, cycle threshold; PIS, patient infection status.

cobas TV/MG assay fulﬁls an unmet medical need for the testing of patients for diagnosis, supports public health efforts toward the control of T. vaginalis, and complements existing STI programs.
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